|Keyword||CPC||PCC||Volume||Score||Length of keyword|
Background: LRRC15 is a member of the LRR (leucine-rich repeat) superfamily present on tumor-associated fibroblasts (CAFs) and stromal cells. The expression of LRRC15 is upregulated by the pro-inflammatory cytokine TGFβ.Is LRRC15 expressed in epithelial tumors?
LRRC15 has been shown to be highly expressed on CAFs within the tumor stroma of many epithelial tumors. By analyzing a small cohort of 39 STS, we have also observed that LRRC15 can also be directly expressed on cancer cells from mesenchymal tumors .Is LRRC15 a potential therapeutic agent in soft-tissue sarcomas?
We report here the first large study assessing LRRC15 expression in mesenchymal malignancies (soft-tissue sarcomas) and its potential therapeutic application in this indication. LRRC15 has been shown to be highly expressed on CAFs within the tumor stroma of many epithelial tumors.Is LRRC15 a promising new therapeutic target in STS?
In summary, LRRC15 represents a promising new therapeutic target in STS based on these data. ABBV-085 is a first-in-class stromal targeting ADC which was well-tolerated in a phase 1 study in patients with advanced sarcomas, with durable partial responses observed in these patients.